This is the authors' abstract. We don't add key points for this paper.
Tenofovir is a new antiretroviral nucleotide analogue with anti-HIV and anti-hepatitis B virus therapeutic properties. Tenofovir disoproxil fumarate, the precursor of tenofovir, is metabolized intracellularly into tenofovir diphosphate, a competitive inhibitor of HIV-1 reverse transcriptase [1]. The use of adefovir in HIV infection, another nucleotide analogue, had been limited because of renal toxicity. Cidofovir, a nucleoside with activity against cytomegalovirus is known to exhibit toxicity for proximal tubular cells, and has been associated with the occurrence of Fanconi syndrome with and without renal failure [2]. We report on a 60-year-old homosexual white man, known to be HIV-1 seropositive for 13 years, who 4 weeks after the onset of treatment with tenofovir (Viread; Gilead Sciences, Foster City, CA, USA) presented with Fanconi syndrome and acute renal failure. The patient was on a sixth line of antiretroviral treatment, and had suffered from numerous complications of antiretroviral therapy, including lipoatrophy, retractile capsulitis of the shoulder when on protease inhibitors, and interstitial pneumopathy attributed to abacavir (Ziagen, GlaxoSmithKline, Philadelphia, USA). After obtaining informed consent, the patient had started a new therapeutic regimen, including ritonavir (Norvir, 100 mg/day; Abbott Laboratories Inc., Illinois, USA) associated with atazanavir (Bristol Myers Squibb, NY, NY, USA, 300 mg/day), for the first 15 days, followed by tenofovir (300 mg/day), within the framework of the ANRS 107 (Agence Nationale de Recherches sur le SIDA, France) treatment study of salvage therapy in patients with multiple failures of antiretroviral agents. Two other antiretroviral agents, didanosine (Videx, 400 mg/day) and stavudine (Zerit, 40 mg twice a day; Bristol Myers Squibb, NY, NY, USA), were continued without dose modification. At initiation of the new regimen, the plasma HIV viral load was 4.04 log, the CD4 T cell count was 318 cells/mm3, and the serum creatinine level was 72 μmol/ml. Four weeks after initiation of therapy with tenofovir, the patient abruptly developed an acute nephritic syndrome characterized by haematuria, proteinuria (3 g/24 h), severe hypertension and acute renal failure, with a serum creatinine level of 351 μmol/l. There was no fever, no clinical evidence of any inflammatory process, nor a monoclonal immunoglobulin peak in serum. Laboratory tests to search for an immunological or infectious process remained negative, including antinuclear antibody, antineutrophil cytoplasmic antibody, cryoglobulin, rheumatoid factor, hepatitis B and hepatitis C virus serologies. Fanconi syndrome was diagnosed on the basis of the presence of metabolic acidosis, glycosuria, phosphaturia, proteinuria and hypouricemia. Urinary cytology revealed large amounts of desquamated cells of apparent tubular origin at various stages of degeneration, varying from cells with pyknotic nuclei to anucleate cells and cytoplasmic fragments. There were also rare clusters of mildly atypical squamous cells, and no evidence of crystals. Renal biopsy revealed lesions that were largely localized to the proximal convoluted tubules. There was generalized necrosis and sloughing of tubular cells, with denuding of the tubular basement membrane. When present, the tubular cell cytoplasm appeared thin and often vacuolated. Nuclei were enlarged, often markedly so, with prominent atypia, some with features suggesting possible viral inclusions. Surrounding the tubules was focal interstitial inflammation of mixed character, without significant destruction of tubular basement membranes. There was neither dilation of the collecting tubules nor any suggestion of crystals. Polarization microscopy revealed no crystals on either paraffin-embedded or frozen sections (see Fig. 1).Fig. 1.: Renal cortex showing necrotic tubular lesions with denuding of the tubular basement membranes of the proximal tubules (P). The distal tubules are normal (D). The proximal convoluted tubules show impressive nuclear changes, with voluminous nuclei seeming to contain inclusions (lower arrow), with other cells multinucleated (top arrow). Masson trichrome × 200.Glomeruli were normal, with no suggestion of HIV-specific lesions such as ‘collapsing glomerulopathy', lupus-like nephropathy or haemolytic-uremic syndrome. Conventional immimmunofluorescence with anti-immunoglobulin and anti-C3 antibodies was negative. Immunohistochemical studies were negative for cytomegalovirus, herpes, adeno, BK, and JC viruses. The latter viruses were also absent from urine (polymerase chain reaction) and renal biopsy (in-situ hybridization). All antiretroviral drugs were discontinued. Subsequently, the serum creatinine level remained stable at approximately 200 μmol/l for 2 months, with a creatinine clearance of 40 ml/min. Tenofovir acts on the proximal tubular cells via the human organic anion transporter 1, which controls its tubular secretion and, partly, the renal elimination of the drug, as is the case for cidofovir and adefovir [3]. Early studies of tenofovir had demonstrated impairment in the intestinal absorption of phosphates, but no cases of proximal tubular dysfunction associated with tenofovir have been reported [1]. Nevertheless, nephrotoxicity has been observed in animals with doses of the drug equivalent to those used in the early clinical trials of tenofovir [4]. The proximal tubular location of renal lesions observed in our patient, associated with an overt Fanconi syndrome, as previously described with cidofovir [2], and the lack of other lesions known to occur in HIV disease, is strongly suggestive that these lesions should be attributed to tenofovir. Tenofovir is increasingly prescribed as an antiretroviral agent in HIV-positive individuals. We believe that regular surveillance for the occurrence of proximal dysfunction, including the search for glycosuria and measurements of creatinine levels, is recommended from the onset of treatment.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Créput et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: